Phase II trial of adjuvant pelvic radiation "sandwiched" between combination paclitaxel and carboplatin in women with uterine papillary serous carcinoma

Objective

To evaluate the safety and survival in women treated with adjuvant pelvic radiation “sandwiched” between six cycles of paclitaxel and carboplatin chemotherapy with completely resected UPSC.

Methods

Surgically staged women with UPSC (FIGO stage 1-4) and no visible residual disease were enrolled. Treatment involved paclitaxel (175 mg/m²) and carboplatin (AUC = 6.0-7.5) every 21 days for 3 doses, followed by radiation therapy (RT), followed by an additional 3 cycles of paclitaxel and carboplatin (AUC = 5-6). Survival analysis, using Kaplan-Meier methods, was performed on patients who completed at least 3 cycles of chemotherapy and RT.

Results

A total of 81 patients were enrolled, of which 72 patients completed the first 3 cycles of chemotherapy followed by prescribed RT. Median age was 67 years (range: 43-82 years). 59/72 (82%) had disease confined to the uterus and 13/72 (18%) had completely resected extra-uterine disease (stage 3 and 4). 65 (83%) completed the protocol. Overall PFS and OS for combined stage 1 and 2 patients was 65.5 ± 3.6 months and 76.5 ± 4.3 months, respectively. PFS and OS for combined stage 3 and 4 patients was 25.8 ± 3.0 and 35.9 ± 5.3 months, respectively. Three-year % survival probability for stage 1 and 2 patients was 84% and for stage 3 and 4 patients was 50%. Of the 435 chemotherapy cycles administered, there were 11(2.5%) G3/G4 non-hematologic toxicities. 26(6.0%) cycles had dose reductions and 37(8.5%) had dose delays.

Conclusions

Compared to prior studies of single modality adjuvant therapy, RT “sandwiched” between paclitaxel and carboplatin chemotherapy is well-tolerated and highly efficacious in women with completely resected UPSC.     

子宫内膜上皮内癌临床病理研究

目的：探讨子宫内膜上皮内癌的临床病理特点,并复习文献,回顾其研究进展,提高对子宫乳头状浆液性癌的前驱病变的认识。方法：收集5例子宫内膜上皮内癌,均经手术病理分期并随访3-5年,通过HE切片、光镜观察和免疫组织化学研究,结合临床随访资料进行临床病理分析。免疫组织化学染色所用一抗为：p53、Ki67、ER和PR。结果：5例患者均为绝经后妇女,年龄57-79岁（平均68岁,中位65岁）,临床表现为阴道流血或阴道排液,1例为子宫脱垂,影像学检查发现子宫萎缩伴＂宫腔息肉＂或＂子宫内膜增厚＂。镜下：活检和术中病理会诊的组织学特点与典型的子宫乳头状浆液性癌相同,但无子宫肌层浸润,即癌组织局限于子宫内膜层内,临床病理分期为TIa期。经全面手术病理分期,未发现子宫外扩展。5例免疫组织化学染色均为p53＋＋＋、Ki67＋＋＋、ER-和PR-。随访3—5年均健在,无复发或转移。结论：子宫内膜上皮内癌罕见,若全面的手术病理分期无子宫外扩展者,有较好临床预后。回顾文献,子宫内膜上皮内癌可能属于一种特殊的早期癌,而子宫内膜腺体异型增生可能是其前驱病变。     

子宫内膜上皮内癌临床病理研究

目的:探讨子宫内膜上皮内癌的临床病理特点,并复习文献,回顾其研究进展,提高对子宫乳头状浆液性癌的前驱病变的认识.方法:收集5例子宫内膜上皮内癌,均经手术病理分期并随访3-5年,通过HE切片、光镜观察和免疫组织化学研究,结合临床随访资料进行临床病理分析.免疫组织化学染色所用一抗为:p53、Ki67、ER和PR.结果:5例患者均为绝经后妇女,年龄57-79岁(平均68岁,中位65岁),临床表现为阴道流血或阴道排液,1例为子宫脱垂,影像学检查发现子宫萎缩伴"宫腔息肉"或"子宫内膜增厚".镜下:活检和术中病理会诊的组织学特点与典型的子宫乳头状浆液性癌相同,但无子宫肌层浸润,即癌组织局限于子宫内膜层内,临床病理分期为TIa期.经全面手术病理分期,未发现子宫外扩展.5例免疫组织化学染色均为p53+++、Ki67+++、ER-和PR-.随访3-5年均健在,无复发或转移.结论:子宫内膜上皮内癌罕见,若全面的手术病理分期无子宫外扩展者,有较好临床预后.回顾文献,子宫内膜上皮内癌可能属于一种特殊的早期癌,而子宫内膜腺体异型增生可能是其前驱病变.